Nisita Dutta
Nisita Dutta has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alan F. Rubin
University of Melbourne
1 shared publication - Buheng Wang
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218
1 shared publication - Christine Alewine
Laboratory of Molecular Biology, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland USA
1 shared publication - Claudio Daniel Navo
Center for Cooperative Research in Biosciences (CIC bioGUNE)
1 shared publication Courtney E. Gonzalez
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218
1 shared publicationDahlia Rohm
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (52) , 48271-48289
Controlled Self-Immolative Release of β-Lapachone via an Optimized para -Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy
Methodologies to target cancer cells without affecting healthy surrounding cells have the potential to vastly improve both patient outcomes and quality of life. ortho-Quinone natural products such as β-lapachone have exhibited great therapeutic potential, but their clinical use has been limited thus far due to systemic toxicity, making them ideal candidates for targeted prodrug development. Previously developed β-lapachone prodrugs suffered from suboptimal release rates, low solubility, and poor tumor specificity, which have hindered their advancement into the clinic. This work explores the development of an optimized β-lapachone small molecule prodrug platform that utilizes a β-glucuronide-protected para-hydroxybenzyl (PHB) moiety alkylated to one of β-lapachone's carbonyls via an indium-mediated Barbier-type reaction. The β-glucuronide moiety detoxifies and solubilizes the ortho-quinone systemically and triggers specific release in the tumor microenvironment (TME). Additionally, the drug release rate is largely controlled by pH and can be fine-tuned via the addition of electron-donating/withdrawing groups to the PHB self-immolative linker. The prodrug is rationally designed to have numerous layers of pancreatic cancer targeting via the tumor-selective overexpression of the key β-lapachone activating enzymes NQO1 and 5-LO, the TME expression pattern of the release-triggering enzyme β-glucuronidase, and the opportunity for modular attachment to carrier systems targeting pancreatic cancer membrane proteins. Various derivatives of this prodrug have shown promising stability, release, and efficacy against pancreatic cancer cell lines. This unique prodrug platform allows us to mask the toxicity of an ortho-quinone payload and utilize several layers of tumor specificity in the hope of effectively treating pancreatic cancer patients while minimizing toxic side effects.
- 15 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (52) , 48271-48289
Open AccessControlled Self-Immolative Release of β-Lapachone via an Optimized para -Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy
Methodologies to target cancer cells without affecting healthy surrounding cells have the potential to vastly improve both patient outcomes and quality of life. ortho-Quinone natural products such as β-lapachone have exhibited great therapeutic potential, but their clinical use has been limited thus far due to systemic toxicity, making them ideal candidates for targeted prodrug development. Previously developed β-lapachone prodrugs suffered from suboptimal release rates, low solubility, and poor tumor specificity, which have hindered their advancement into the clinic. This work explores the development of an optimized β-lapachone small molecule prodrug platform that utilizes a β-glucuronide-protected para-hydroxybenzyl (PHB) moiety alkylated to one of β-lapachone's carbonyls via an indium-mediated Barbier-type reaction. The β-glucuronide moiety detoxifies and solubilizes the ortho-quinone systemically and triggers specific release in the tumor microenvironment (TME). Additionally, the drug release rate is largely controlled by pH and can be fine-tuned via the addition of electron-donating/withdrawing groups to the PHB self-immolative linker. The prodrug is rationally designed to have numerous layers of pancreatic cancer targeting via the tumor-selective overexpression of the key β-lapachone activating enzymes NQO1 and 5-LO, the TME expression pattern of the release-triggering enzyme β-glucuronidase, and the opportunity for modular attachment to carrier systems targeting pancreatic cancer membrane proteins. Various derivatives of this prodrug have shown promising stability, release, and efficacy against pancreatic cancer cell lines. This unique prodrug platform allows us to mask the toxicity of an ortho-quinone payload and utilize several layers of tumor specificity in the hope of effectively treating pancreatic cancer patients while minimizing toxic side effects.
- 8 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (21) , 11597-11607
Collateral fitness effects of mutations
The distribution of fitness effects of mutation plays a central role in constraining protein evolution. The underlying mechanisms by which mutations lead to fitness effects are typically attributed to changes in protein specific activity or abundance. Here, we reveal the importance of a mutation’s collateral fitness effects, which we define as effects that do not derive from changes in the protein’s ability to perform its physiological function. We comprehensively measured the collateral fitness effects of missense mutations in the Escherichia coli TEM-1 β-lactamase antibiotic resistance gene using growth competition experiments in the absence of antibiotic. At least 42% of missense mutations in TEM-1 were deleterious, indicating that for some proteins collateral fitness effects occur as frequently as effects on protein activity and abundance. Deleterious mutations caused improper posttranslational processing, incorrect disulfide-bond formation, protein aggregation, changes in gene expression, and pleiotropic effects on cell phenotype. Deleterious collateral fitness effects occurred more frequently in TEM-1 than deleterious effects on antibiotic resistance in environments with low concentrations of the antibiotic. The surprising prevalence of deleterious collateral fitness effects suggests they may play a role in constraining protein evolution, particularly for highly expressed proteins, for proteins under intermittent selection for their physiological function, and for proteins whose contribution to fitness is buffered against deleterious effects on protein activity and protein abundance.
- 8 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (21) , 11597-11607
Collateral fitness effects of mutations
The distribution of fitness effects of mutation plays a central role in constraining protein evolution. The underlying mechanisms by which mutations lead to fitness effects are typically attributed to changes in protein specific activity or abundance. Here, we reveal the importance of a mutation’s collateral fitness effects, which we define as effects that do not derive from changes in the protein’s ability to perform its physiological function. We comprehensively measured the collateral fitness effects of missense mutations in the Escherichia coli TEM-1 β-lactamase antibiotic resistance gene using growth competition experiments in the absence of antibiotic. At least 42% of missense mutations in TEM-1 were deleterious, indicating that for some proteins collateral fitness effects occur as frequently as effects on protein activity and abundance. Deleterious mutations caused improper posttranslational processing, incorrect disulfide-bond formation, protein aggregation, changes in gene expression, and pleiotropic effects on cell phenotype. Deleterious collateral fitness effects occurred more frequently in TEM-1 than deleterious effects on antibiotic resistance in environments with low concentrations of the antibiotic. The surprising prevalence of deleterious collateral fitness effects suggests they may play a role in constraining protein evolution, particularly for highly expressed proteins, for proteins under intermittent selection for their physiological function, and for proteins whose contribution to fitness is buffered against deleterious effects on protein activity and protein abundance.
- 11 September 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (38) , 12069-12076
DNA Strand Buffers
A buffer reaction actively resists changes to the concentration of a chemical species. Typically, buffering reactions have only been able to regulate the concentration of hydronium (i.e., pH) and other ions. Here, we develop a new class of buffers that regulate the concentrations of short sequences of DNA (i.e., oligonucleotides). A buffer’s behavior is determined by its set point concentration, capacity to resist disturbances, and response time after a disturbance. We provide simple mathematical formulas for selecting rate constants to tune each of these properties and show how to design DNA sequences and concentrations to implement the desired rate constants. We demonstrate several oligonucleotide buffers that maintain oligonucleotide set point concentrations between 10 and 80 nM in the presence of disturbances of 50 to 500 nM, with response times of less than 10 min to 1.5 h. Multiple buffers can regulate different sequences of DNA in parallel without crosstalk. Oligonucleotide buffers could stabilize and restore reactant concentrations in DNA circuits or in self-assembly processes, allowing such systems to operate reliably for extended durations. These buffers might also be coupled to other reactions to buffer molecules other than DNA. In general, an oligonucleotide buffer can be viewed as a chemical “battery” that maintains the total chemical potential of a buffered species in a closed system.
- 11 September 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (38) , 12069-12076
DNA Strand Buffers
A buffer reaction actively resists changes to the concentration of a chemical species. Typically, buffering reactions have only been able to regulate the concentration of hydronium (i.e., pH) and other ions. Here, we develop a new class of buffers that regulate the concentrations of short sequences of DNA (i.e., oligonucleotides). A buffer’s behavior is determined by its set point concentration, capacity to resist disturbances, and response time after a disturbance. We provide simple mathematical formulas for selecting rate constants to tune each of these properties and show how to design DNA sequences and concentrations to implement the desired rate constants. We demonstrate several oligonucleotide buffers that maintain oligonucleotide set point concentrations between 10 and 80 nM in the presence of disturbances of 50 to 500 nM, with response times of less than 10 min to 1.5 h. Multiple buffers can regulate different sequences of DNA in parallel without crosstalk. Oligonucleotide buffers could stabilize and restore reactant concentrations in DNA circuits or in self-assembly processes, allowing such systems to operate reliably for extended durations. These buffers might also be coupled to other reactions to buffer molecules other than DNA. In general, an oligonucleotide buffer can be viewed as a chemical “battery” that maintains the total chemical potential of a buffered species in a closed system.